1. Home
  2. DCOY vs GOVX Comparison

DCOY vs GOVX Comparison

Compare DCOY & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Decoy Therapeutics Inc. Common Stock

DCOY

Decoy Therapeutics Inc. Common Stock

N/A

Current Price

$1.56

Market Cap

3.2M

Sector

Health Care

ML Signal

N/A

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

N/A

Current Price

$0.29

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DCOY
GOVX
Founded
N/A
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.0M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
DCOY
GOVX
Price
$1.56
$0.29
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $10.00
AVG Volume (30 Days)
★ 4.1M
783.6K
Earning Date
11-16-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $2,489,145.00
Revenue This Year
N/A
N/A
Revenue Next Year
$20.42
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.53
$0.12
52 Week High
$13.51
$4.40

Technical Indicators

Market Signals
Indicator
DCOY
GOVX
Relative Strength Index (RSI) 29.82 20.70
Support Level $0.61 $0.16
Resistance Level $3.29 $0.86
Average True Range (ATR) 0.69 0.04
MACD -0.10 0.01
Stochastic Oscillator 0.33 7.71

Price Performance

Historical Comparison
DCOY
GOVX

About DCOY Decoy Therapeutics Inc. Common Stock

Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Share on Social Networks: